{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-29.0","upperLimit":"27.0","value":"-5.0"},{"groupId":"OG001","lowerLimit":"-32.0","upperLimit":"22.0","value":"-4.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"317"},{"groupId":"OG001","value":"157"}],"units":"Participants"}],"description":"FACIT-F is a 13-item questionnaire. Patients scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the patient's response to the questions (with the exception of 2 negatively stated), the greater the patient's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the patient's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflects an improvement in the patient's health status.","dispersionType":"Full Range","groups":[{"description":"1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by re-treatment during weeks 24 -40 consisting of two additional doses of 1000 mg rituximab 14 days apart plus 10-25 mg/week methotrexate.","id":"OG000","title":"Arm A: Rituximab Re-treatment"},{"description":"1000 mg rituximab initial treatment on day 1 and day 15 plus 10-25 mg/wk methotrexate followed by re-treatment during weeks 24 -40 consisting of two doses of placebo 14 days apart plus 10-25 mg/wk methotrexate.","id":"OG001","title":"Arm B: Placebo Re-treatment"}],"paramType":"MEDIAN","populationDescription":"Participants from the Intent-to-treat population, that includes all randomized participants, with data available for analyses.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 48","title":"Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) at Week 48 in Retreated Subjects","type":"SECONDARY","unitOfMeasure":"Score on a scale"}